5/16
07:30 am
zlab
Zai Lab Announces Participation in May and June Investor Conferences
Medium
Report
Zai Lab Announces Participation in May and June Investor Conferences
5/14
07:42 am
zlab
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China [Yahoo! Finance]
Low
Report
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China [Yahoo! Finance]
5/14
07:30 am
zlab
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Low
Report
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
5/13
11:53 am
zlab
BMS and Zai Lab's Augtyro gains NMPA approval to treat NSCLC [Yahoo! Finance]
Medium
Report
BMS and Zai Lab's Augtyro gains NMPA approval to treat NSCLC [Yahoo! Finance]
5/12
08:25 pm
zlab
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA [Yahoo! Finance]
Medium
Report
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA [Yahoo! Finance]
5/12
08:20 pm
zlab
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
Medium
Report
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
5/11
08:37 am
zlab
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates [Yahoo! Finance]
Medium
Report
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates [Yahoo! Finance]
5/10
05:29 pm
zlab
Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/10
04:31 pm
zlab
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
01:08 am
zlab
argenx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
argenx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/8
04:12 pm
zlab
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
High
Report
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
5/8
04:05 pm
zlab
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
High
Report
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
5/2
07:13 am
zlab
Novocure Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Novocure Reports First Quarter 2024 Financial Results [Yahoo! Finance]
4/30
07:34 am
zlab
Zai Lab Limited's (NASDAQ:ZLAB) Profit Outlook [Yahoo! Finance]
Low
Report
Zai Lab Limited's (NASDAQ:ZLAB) Profit Outlook [Yahoo! Finance]
4/16
05:20 pm
zlab
A Risky Bet: Zai Lab's Uncertain Future [Seeking Alpha]
Medium
Report
A Risky Bet: Zai Lab's Uncertain Future [Seeking Alpha]
4/15
07:30 am
zlab
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Low
Report
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
4/11
07:37 am
zlab
Zai Lab Statement on Executive Management Team's Agreement on Share Activities [Yahoo! Finance]
Medium
Report
Zai Lab Statement on Executive Management Team's Agreement on Share Activities [Yahoo! Finance]
4/11
07:30 am
zlab
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Medium
Report
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
4/2
07:39 am
zlab
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs [Yahoo! Finance]
Low
Report
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs [Yahoo! Finance]
4/2
07:30 am
zlab
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Low
Report
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
4/1
11:47 am
zlab
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago [Yahoo! Finance]
Medium
Report
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago [Yahoo! Finance]
4/1
07:38 am
zlab
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... [Yahoo!
Low
Report
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... [Yahoo!
4/1
07:30 am
zlab
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
Medium
Report
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
3/27
09:40 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
Neutral
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
3/27
09:29 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Low
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer